SCHEMBL640686

SCHEMBL640686

COC(=O)C(c1cccc(OC)c1)n1c(=O)n(C(=O)OC(C)(C)C)c2ccc(Cl)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
IDO1 P14902 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.35
CBX7 O95931 1/20 0.35
CDYL2 Q8N8U2 1/20 0.35
CDYL Q9Y232 1/20 0.35
CDY1; CDY1B Q9Y6F8 1/20 0.35
NR1H2 P55055 1/20 0.35
CCR2 P41597 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
GFER P55789 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640432 0.90 MDM2 (0.41) MEN1KMT2AL3MBTL1LMNACCR2
SCHEMBL640324 0.88 MEN1 (0.41) MEN1KMT2AIDO1L3MBTL1LMNA
SCHEMBL642618 0.83 LMNA (0.41) MEN1KMT2AL3MBTL1LMNANR1H2
SCHEMBL639820 0.83 LMNA (0.38) MEN1KMT2AL3MBTL1LMNANR1H2
SCHEMBL641167 0.80 L3MBTL1 (0.48) MEN1KMT2AL3MBTL1LMNASMN1; SMN2
SCHEMBL642977 0.80 LMNA (0.44) MEN1KMT2AL3MBTL1LMNANR1H2
SCHEMBL640641 0.76 LMNA (0.37) MEN1KMT2AL3MBTL1LMNASMN1; SMN2
SCHEMBL25232919 0.73 CCR2 (0.55) MEN1KMT2AIDO1L3MBTL1LMNA
SCHEMBL30336999 0.73 CCR2 (0.55) MEN1KMT2AIDO1L3MBTL1LMNA
SCHEMBL639895 0.71 GABRG2 (0.41) NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MEN1 43/4885KMT2A 4356/4885IDO1 1288/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MEN1 43/4885KMT2A 4356/4885IDO1 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.